We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Certain Cytokines Not Associated with Severity of COVID-19 Symptoms

By LabMedica International staff writers
Posted on 24 Jun 2020
Print article
Image: This illustration reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically (Photo courtesy of Centers for Disease Control and Prevention).
Image: This illustration reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically (Photo courtesy of Centers for Disease Control and Prevention).
The pandemic outbreak of coronavirus disease 2019 (COVID-19) is sharply spreading all over the world. The severity of a viral disease usually is positive association with immune-mediated inflammatory responses. The aggressive and persistent inflammatory response leads to high risk of multiorgan failure and death.

The overproduction inflammatory cytokines results in cytokine storm. Cytokine storm indicates excessive release of pro-inflammatory cytokines including C-reactive protein (CRP) and pro-inflammatory cytokines (IL-2, IL-4, TNF-α, IFN-γ). There is a body of evidences suggests that severe COVID-19 patients have cytokine storm.

Scientists at the Harbin Medical University (Harbin, China) and their colleagues studied patients aged 39 to 85 years old, who were confirmed to be SARS-CoV-2 positive via nasopharyngeal swabs. Further, clinical characteristics and chest CT scans indicated that these patients had severe COVID-19. All patients were admitted in ICU with hypoxemic respiratory failure. Of these patients, five (20%) had hypertension and five (20%) had diabetes. All 25 patients were discharged from the ICU to the hospital ward before being discharged home.

The scientists analyzed serum inflammatory cytokines and immune cells in these patients and found that CRP (range: 0.499-9.75 mg/L; reference value: 0-10 mg/L), IL-2 (range: 0.67-2.59 pg/L; reference value: 0.08-5.71 pg/mL), IL-4 (range: 0-2.27 pg/L; reference value: 0.1-2.8 pg/L), TNF-α (range: 0-1.86 pg/L; reference value: 0.1-2.31 pg/L) and IFN-γ (range: 0.51-3.24 pg/L; reference value: 0.16-7.42 pg/L) were in the normal value range compared to the reference value. These cases showed that IL-2, IL-4, TNF-α, IFN-γ and C reactive protein level is not associated with severe COVID-19 pathology.

The investigators also reported that levels of IL-6 and IL-10 in some severe COVID-19 patients were over the reference values, indicating that these patients had severe clinical characteristics independent of circulating levels of IL-2, IL-4, TNF-α, IFN-γ and CRP. IL-6 levels in 16 patients were above the reference range of 1.18-5.3 pg/L, with levels of 0-36.3 pg/L recorded in all 25 patients. In addition, 14 patients had IL-10 levels above the reference range of 0.19-4.91 pg/L, with levels of 4.96-12.44 pg/L observed across the 25 patients.

The authors concluded that some reports had shown cytokine storm was correlated with severity and mortality of COVID-19 patients, but the correlation does not indicate causation. More viral replication also could drive consequent severity of COVID-19. The authors said that the hypothesis that blocking cytokine storm eases COVID-19 severity needs to be more carefully investigated based on their observation. The study was published on June 10, 2020 in the Journal of Medical Virology.

Related Links:
Harbin Medical University

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.